Ballabh P, Simm M, Kumari J, Krauss A N, Jain A, Califano C, Lesser M L, Cunningham-Rundles S
Division of Neonatology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, USA.
Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F76-83. doi: 10.1136/fn.89.1.f76.
To study a longitudinal change in the expression of adhesion molecules CD11b, CD18, and CD62L on neutrophils and monocytes in very low birth weight babies who develop respiratory distress syndrome, to compare these levels between bronchopulmonary dysplasia (BPD) and non-BPD infants, and to assess the effect of corticosteroid treatment on these adhesion molecules.
Of 40 eligible neonates, 11 neonates were oxygen dependent at 36 weeks (BPD 36 weeks), 16 infants were oxygen dependent at 28 days, but not at 36 weeks (BPD d28), and 13 infants did not develop BPD. Seventeen neonates received a six day course of steroid treatment. Expression of CD11b, CD18, and CD62L was measured on neutrophils and monocytes in arterial blood on days 1, 3, 7, 14, 21, and 28, and before and 2-3 days after initiation of dexamethasone treatment by flow cytometry.
CD18 expression on neutrophils and monocytes and CD62L on neutrophils, measured as mean fluorescent intensity, was significantly decreased in BPD neonates compared to non-BPD neonates on days 1-28. Dexamethasone treatment significantly decreased CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18L expression on monocytes.
Decreased CD18 expression on neutrophils and monocytes, and decreased CD62L expression on neutrophils, measured as mean fluorescent intensity during the first four weeks of life in micropremies may be risk factors and early predictors of BPD. Dexamethasone use was associated with decreased expression of CD11b, CD18, and CD62L.
研究患有呼吸窘迫综合征的极低出生体重儿中性粒细胞和单核细胞上黏附分子CD11b、CD18和CD62L表达的纵向变化，比较支气管肺发育不良（BPD）婴儿和非BPD婴儿的这些水平，并评估皮质类固醇治疗对这些黏附分子的影响。
在40名符合条件的新生儿中，11名新生儿在36周时仍依赖氧气（36周BPD），16名婴儿在28天时依赖氧气，但在36周时不依赖（28天BPD），13名婴儿未发生BPD。17名新生儿接受了为期6天的类固醇治疗。在第1、3、7、14、21和28天以及地塞米松治疗开始前和开始后2 - 3天，通过流式细胞术测量动脉血中中性粒细胞和单核细胞上CD11b、CD18和CD62L的表达。
在第1 - 28天，与非BPD新生儿相比，BPD新生儿中性粒细胞和单核细胞上的CD18表达以及中性粒细胞上的CD62L表达（以平均荧光强度衡量）显著降低。地塞米松治疗显著降低了中性粒细胞上CD11b、CD18和CD62L的表达，以及单核细胞上CD11b和CD18L的表达。
在超低出生体重儿出生后的前四周内，以平均荧光强度衡量，中性粒细胞和单核细胞上CD18表达降低以及中性粒细胞上CD62L表达降低可能是BPD的危险因素和早期预测指标。使用地塞米松与CD11b、CD18和CD62L表达降低有关。
